


# Drug Discovery Technology (TechVision)

*Drug discovery and biomanufacturing technology for drug delivery, across cancer, autoimmune diseases, and rare disorders*



D951-TV

January 8, 2016



# Contents

Section	Slide Numbers
<a href="#"><u>Innovations in drug delivery, across cancer, autoimmune diseases, and rare disorders</u></a>	3
<a href="#"><u>Drug Discovery Platform to Target Cancer Stem Cells</u></a>	4
<a href="#"><u>Multi-Biomarker Blood Test for Rheumatoid Arthritis</u></a>	5
<a href="#"><u>Precision Encapsulation for Optimal Drug Delivery</u></a>	6
<a href="#"><u>Multi-Protein Clusters as Novel Drug Discovery Tools</u></a>	7
<a href="#"><u>New Treatment for Patients with Lysosomal Acid Lipase Deficiency</u></a>	8
<a href="#"><u>Treatment for Bilateral Otitis Media Gets FDA Nod</u></a>	9
<a href="#"><u>New Treatment Option for Metastatic Adenocarcinoma of Pancreas</u></a>	10
<a href="#"><u>Appendix</u></a>	11
<a href="#"><u>Patent Analysis</u></a>	12
<a href="#"><u>Industry Interactions</u></a>	14

**Innovations in drug delivery, across cancer,  
autoimmune diseases, and rare disorders**

# Drug Discovery Platform to Target Cancer Stem Cells

*Bionomics Limited—CSC Rx Discovery Platform™*

## Technology Profile

### CSC Rx Discovery Platform™

Aims to discover highly active, functional therapeutic antibodies and small molecule candidates that target cancer stem cells (CSCs).

## Competing Aspects

Bionomics has two principal strategies. The first is to achieve best-in-class quality attributes for drug candidates. ....

## Innovation Attributes

Unique discovery platform that specifically and effectively identifies anti-CSC therapeutics. CSCs are well-known to play a critical role in tumor initiation, recurrence, and metastasis. ...

## Market Entry Strategies

Bionomics has a portfolio of well differentiated drug candidates, not only limited to cancer therapeutics, ...

## Technology Readiness Level



*CSC Rx Discovery Platform™ is available for licensing through partnerships.*

**Bionomics**

## Impact & Opportunities

### Wide-scale Adoption

Bionomics has partnered with Merck, Cancer Therapeutics CRC, Genmab A/S, LabCorp, Athena Diagnostics, and Genetic Technologies Limited, among others.

...

### Market Opportunity and Technology Convergence

Bionomics is open to partnership in relation to

- BNC105, a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy,
- ...
- ....

# Appendix

# Patent Analysis

Rivaroxaban is an oral anticoagulant that was originally developed by Bayer AG and is often marketed by different manufacturers under different trade names in various countries. One of the key highlights of the product is its excellent absorption in the human gut leading to the inhibition of factor Xa approximately four hours after dosing. Although the effects of rivaroxaban dose lasts for about 8-12 hours, the activity of factor Xa returns only after 24 hours of dosing. The drug has been found effective in preventing embolic events and non-hemorrhagic strokes and is also associated with lower rates of bleeding in cardiovascular indications. Patents in Exhibit 1 present a number of methods for the preparation of rivaroxaban especially through the crystallization process. The patents covered in Exhibit 1 also discuss novel pharmaceutical compositions comprising rivaroxaban and H2-receptor antagonists in preventing coagulations associated with gastrointestinal disorders apart from reducing the risk of hemmorrhage. The pharmaceutical salt containing rivaroxaban usually has better metabolic characteristics and a better oral bioavailability than other commonly available anticoagulants.

*Picture Credit: Frost & Sullivan; WIPO Database*

# Industry Interactions